Highlights in clinical autonomic neurosciences: Clinical update on multiple system atrophy. | Read by QxMD (original) (raw)
Multiple system atrophy (MSA) may be the most feared of diseases affecting the autonomic nervous system. Accordingly, concerted efforts are underway to elucidate further its pathophysiology with the objective of discovering effective neuroprotective interventions that can slow or halt its progression. Although the epidemiology of MSA is sporadic rather than familial, recently reported associations with COQ2 and C9orf72 suggest that in some cases genetic factors may influence the risk of developing the disease. Research has also identified prion-like characteristics of the expansion of pathologic α-synuclein in the central nervous system. A large clinical trial of rifampicin, which disaggregates and inhibits the formation of α-synuclein fibrils, however, was clearly negative. Other research has shown the importance of recognizing and treating vocal cord paralysis, which is associated with adverse prognosis.
Full text links
We have located links that may give you full text access.
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-
2024
by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our
and
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app